Evaluation of efficacy of combined topical Bimatoprost and Fractionated carbon dioxide laser versus Bimatoprost alone in treatment of alopecia areata

Evaluation of efficacy of combined topical Bimatoprost and Fractionated carbon dioxide laser versus Bimatoprost alone in treatment of alopecia areata patients

Status

Recruiting

Phases

Phase 2

Study type

Interventional

Source

IRCT

Registry ID

IRCT20210715051895N1

Enrollment

Registered

2021-09-21

Start date

2021-08-23

Completion date

Unknown

Last updated

2021-11-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Alopecia areata. Alopecia areata

Interventions

Intervention 1: Intervention group: Combination therapy with CO2 laser and topical bimatoprost.03%. How to use: Fractional CO2 laser treatment is performed once every two weeks for three months and i

Italy

fractional scanning mode

one pulse

spot size=15mm

power=5w

dwell time=500ms

smart stack=3

spacing=700microm

density8.7%

fluence=4.68j/cm2

energy=51.6mj . The patient will receive topical bimatoprost .03% (EXCILIA .03% 3ml sterile solution, IRAN, INOCLON) twice a day, with a cotton applicator in the area of alopecia patch for three month

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: Alopecia areata patients who have two similar alopecia patches on the scalp

Exclusion criteria

Exclusion criteria: pregnancy lactation history of allergy to prostaglandin analouge Taking medication or treatment for the past three months that affects the hair cycle Uncontrolled systemic disease Non-patchy alopecia areata and involving area other than the scalp photosensivity

Design outcomes

Primary

Measure	Time frame
Alopecia patch area. Timepoint: at base line ,4,8,12,24 weeks later. Method of measurement: Measurement of hair regrowth rate by physical examination based on Salt score scale.;Patient satisfaction. Timepoint: 4,8,12,24 weeks later. Method of measurement: By 7point global-assessment patient satisfaction questionnaire.	—

Secondary

Measure	Time frame
Erythema. Timepoint: 4,8,12 Weeks from the beginning of treatment. Method of measurement: By clinical examination and classification of severity of complications into mild, moderate and severe.;Scaling. Timepoint: 4,8,12 Weeks from the beginning of treatment. Method of measurement: By clinical examination and classification of severity of complications into mild, moderate and severe.;Skin dryness. Timepoint: 4,8,12 Weeks from the beginning of treatment. Method of measurement: By clinical examination and classification of severity of complications into mild, moderate and severe.;Pruritis. Timepoint: 4,8,12 Weeks from the beginning of treatment. Method of measurement: By clinical examination and classification of severity of complications into mild, moderate and severe.	—

Measure

Time frame

Erythema. Timepoint: 4,8,12 Weeks from the beginning of treatment. Method of measurement: By clinical examination and classification of severity of complications into mild, moderate and severe.;Scaling. Timepoint: 4,8,12 Weeks from the beginning of treatment. Method of measurement: By clinical examination and classification of severity of complications into mild, moderate and severe.;Skin dryness. Timepoint: 4,8,12 Weeks from the beginning of treatment. Method of measurement: By clinical examination and classification of severity of complications into mild, moderate and severe.;Pruritis. Timepoint: 4,8,12 Weeks from the beginning of treatment. Method of measurement: By clinical examination and classification of severity of complications into mild, moderate and severe.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactSimin Shamsimeymandi

Kerman University of Medical Sciences

meymandi_s@hotmail.com+98 34 3132 8328

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026